How to buy Theratechnologies stock | $2.27

Theratechnologies Inc is a drug manufacturers-specialty & generic business based in the US. Theratechnologies shares (THTX) are listed on the NASDAQ and all prices are listed in US Dollars. Theratechnologies employs 42 staff and has a trailing 12-month revenue of around USD$63.3 million.

How to buy shares in Theratechnologies

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Theratechnologies. Find the stock by name or ticker symbol: THTX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Theratechnologies reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$2.27, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Theratechnologies, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Theratechnologies. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Theratechnologies share price

Use our graph to track the performance of THTX stocks over time.

Theratechnologies shares at a glance

• Key figures

Information last updated 2020-12-10.

Latest market close	USD$2.27
52-week range	USD$1.33 - USD$3.32
50-day moving average	USD$2.1917
200-day moving average	USD$2.2581
Wall St. target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.2921

Buy Theratechnologies shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Theratechnologies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Theratechnologies Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Theratechnologies price performance over time

Historical closes compared with the close of $2.27 from 2020-12-09

1 week (2021-01-06)	N/A
1 month (2020-12-13)	N/A
3 months (2020-10-13)	N/A
6 months (2020-07-13)	N/A

1 year (2020-01-13)	N/A
2 years (2019-01-13)	N/A
3 years (2018-01-13)	N/A
5 years (2016-01-13)	N/A

Is Theratechnologies under- or over-valued?

Valuing Theratechnologies stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Theratechnologies's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Theratechnologies's EBITDA

Theratechnologies's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$4.3 million.

The EBITDA is a measure of a Theratechnologies's overall financial performance and is widely used to measure a its profitability.

Theratechnologies financials

Revenue TTM	USD$63.3 million
Gross profit TTM	USD$31.2 million
Return on assets TTM	-11.48%
Return on equity TTM	-122.31%
Profit margin	-37.22%
Book value	N/A
Market capitalisation	USD$176.6 million

TTM: trailing 12 months

Shorting Theratechnologies shares

There are currently 1.8 million Theratechnologies shares held short by investors – that's known as Theratechnologies's "short interest". This figure is 6.6% up from 1.7 million last month.

There are a few different ways that this level of interest in shorting Theratechnologies shares can be evaluated.

Theratechnologies's "short interest ratio" (SIR)

Theratechnologies's "short interest ratio" (SIR) is the quantity of Theratechnologies shares currently shorted divided by the average quantity of Theratechnologies shares traded daily (recently around 87099.90521327). Theratechnologies's SIR currently stands at 21.1. In other words for every 100,000 Theratechnologies shares traded daily on the market, roughly 21100 shares are currently held short.

However Theratechnologies's short interest can also be evaluated against the total number of Theratechnologies shares, or, against the total number of tradable Theratechnologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Theratechnologies's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Theratechnologies shares in existence, roughly 20 shares are currently held short) or 0.0241% of the tradable shares (for every 100,000 tradable Theratechnologies shares, roughly 24 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Theratechnologies.

Find out more about how you can short Theratechnologies stock.

Theratechnologies share dividends

We're not expecting Theratechnologies to pay a dividend over the next 12 months.

Theratechnologies share price volatility

Over the last 12 months, Theratechnologies's shares have ranged in value from as little as $1.33 up to $3.32. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Theratechnologies's is 1.6771. This would suggest that Theratechnologies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Theratechnologies overview

Theratechnologies Inc., a biopharmaceutical company, markets prescription products in the United States, Europe, and Canada. It offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. The company's pipeline products include F8 Formulation that could be used for the treatment of HIV-associated lipodystrophy; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was founded in 1993 and is headquartered in Montreal, Canada.

Frequently asked questions

• What percentage of Theratechnologies is owned by insiders or institutions?

  Currently 1.523% of Theratechnologies shares are held by insiders and 15.453% by institutions.

• How many people work for Theratechnologies?

  Latest data suggests 42 work at Theratechnologies.

• When does the fiscal year end for Theratechnologies?

  Theratechnologies's fiscal year ends in November.

• Where is Theratechnologies based?

  Theratechnologies's address is: 2015 Peel Street, Montreal, QC, Canada, H3A 1T8

• What is Theratechnologies's ISIN number?

  Theratechnologies's international securities identification number is: CA88338H1001

• What is Theratechnologies's CUSIP number?

  Theratechnologies's Committee on Uniform Securities Identification Procedures number is: 88338H100